Document is current
Any future updates will be listed below
-
Authors
Park, Julien https://orcid.org/0000-0003-2305-9948
Bremova-Ertl, Tatiana
Brands, Marion
Foltan, Tomas
Gautschi, Matthias
Gissen, Paul
Hahn, Andreas
Jones, Simon
Arash-Kaps, Laila
Kolnikova, Miriam
Patterson, Marc
Perlman, Susan
Ramaswami, Uma
Reichmannová, Stella
Rohrbach, Marianne
Schneider, Susanne A.
Shaikh, Aasef
Sivananthan, Siyamini
Synofzik, Matthis
Walterfarng, Mark
Wibawa, Pierre
Martakis, Kyriakos
Manto, Mario
-
Funding
Funding for this research was provided by:
Universität Münster
- License Information
-
More Information
Article History
Received: 19 July 2024
Revised: 18 August 2024
Accepted: 23 August 2024
First Online: 3 September 2024
Declarations
:
: T. Bremova-Ertl received honoraria for lecturing from Sanofi and Acetlion and fees from IntraBio to serve as a blinded rater for the IB1001-201 and IB1001-202 clinical trials. P. Gissen received consulting fees from Mandos Health and is the Co-Founder and shareholder of Bloomsbury Genetic Therapies. M. Patterson is a shareholder in IntraBio and his institution has received research grants from Azafaros, Glycomine, Idorsia, Maggie’s Pearl, Takeda, and Zevra, and consulting fees (directed to his institution) from Zevra. U. Ramaswami has received research and/or investigator-initiated research grants from Amicus and Takeda and honoraria for advisory boards and lectures from Amicus, Takeda, and Sanofi. All other authors. The authors have no competing interests to declare that are relevant to the content of this article.
